The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Schizophrenia: More dopamine, more D 2 receptors
Open accessAbstract
Schizophrenia is a major therapeutic challenge of modern medicine, and one of the last frontiers of brain research. The illness is defined by delusions, hallucinations, disorganized behavior, and cognitive difficulties such as memory loss. It occurs in ≈1% of the world population and usually first appears in early adulthood. Although antipsychotic medications have dramatically improved the lives of patients with schizophrenia, the causes of the illness remain unknown. Of the many contemporary theories of schizophrenia, the most enduring has been the dopamine hypothesis. As originally put by Van Rossum in 1967 (ref. 1, p. 321), “When the hypothesis of dopamine blockade by neuroleptic agents can be further substantiated, it may have fargoing consequences for the pathophysiology of schizophrenia. Overstimulation of dopamine receptors could be part of the aetiology … [emphasis added].” Indeed, this speculative sentence by Van Rossum foreshadows the title of the important work by Abi-Dargham et al . (2) in this issue of PNAS: “Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.” The discovery of the antipsychotic/dopamine receptor (3, 4), now commonly known as the dopamine D2 receptor, led to repeated confirmation that it is the primary site of action for all antipsychotics (3–5), including clozapine and quetiapine (6). All these drugs have different potencies at the receptor. The potency depends on the drug's dissociation constant at D2, which, in turn, relates to the rate of release of the drug from the D2 receptor. For example, the dopamine D2 receptor releases clozapine and quetiapine more rapidly than it does any of the other antipsychotic drugs (7, 8). Given the tight correlation between the clinical potency and the D2-blocking action of the antipsychotic medications, dopamine overactivity could be the common denominator in the …
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, on a neurophysiological level, a prediction error of this nature could cause an increase in the phasic activity of midbrain dopaminergic neurons, given the role that these particular neurons are believed to play in signaling salience in general and prediction errors in particular.[62][63][64][65]”
From Schizophrenia, myelination, and delayed corollary discharges: a hypothesis (2012) · cites this paper as [64]
In the citing paper
“This scenario may be more relevant to the prediction errors we hypothesize to occur in schizophrenia patients, given that it is not clear that these particular predictions (eg, regarding the sensory consequences of self-generated actions) necessarily relate to reward conditioning.”
From Schizophrenia, myelination, and delayed corollary discharges: a hypothesis (2012) · cites this paper as [64]
In the citing paper
“dopaminergic neurons have also been found to ''increase'' their firing rates in response to unpredictable and salient stimuli that are not conditioned to reward.63,64”
From Schizophrenia, myelination, and delayed corollary discharges: a hypothesis (2012) · cites this paper as [64]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Self-citationLaruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291
Breier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154
Increased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020
Kapur, S., Zipursky, R. B., & Remington, G. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.286 · Cited by 711
Self-citationBrain receptors for antipsychotic drugs and dopamine: direct binding assays.
Seeman, P. M., Chau-Wong, M., Tedesco, J., & Wong, K. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.11.4376 · Cited by 702
Self-citation(1962) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1962.tb27008.x · Cited by 594
D2 Dopamine Receptors in Neuroleptic-Naive Schizophrenic Patients
Farde, L. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810150013003 · Cited by 529
Location of a Major Susceptibility Locus for Familial Schizophrenia on Chromosome 1q21-q22
Brzustowicz, L. M., Hodgkinson, K. A., Chow, E. W. C., Honer, W. G., & Bassett, A. S. (2000) · Science · doi:10.1126/science.288.5466.678 · Cited by 516
Burt, D. R., Creese, I., & Snyder, S. H. (1976) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10800-6 · Cited by 482
Research works printed but not linked: 7
- J Van Rossum Neuropsychopharmacology, Proceedings Fifth Collegium Internationale Neuropsychopharmacologicum, eds H Brill, J Cole, P Deniker, H Hippius, P B Bradley (Excerpta Medica, Amsterdam), pp. 321–329 (1967).
- D R Burt, I Creese, S H Snyder Mol Pharmacol 12, 800–812 (1976).
- Kapur S. Zipursky R. Jones C. Shammi C. S. Remington G. & Seeman P. (2000) Arch. Gen. Psychiatry in press.
- S Kapur, P Seeman J Psychiatr Neurosci 25, 161–166 (2000).
- P Seeman Neuropsychopharmacology 7, 261–284 (1992).
- A C Barton, L E Black, D R Sibley Mol Pharmacol 39, 650–658 (1991).
- M Itokawa, M Toru, K Ito, H Tsuga, K Kameyama, T Haga, T Arinami, H Hamaguchi Mol Pharmacol 49, 560–566 (1996).
Cited by
Sorted by citations
Kapur, S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.13 · Cited by 2,813
Self-citationHalf a century of antipsychotics and still a central role for dopamine D2 receptors
Kapur, S., & Mamo, D. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.004 · Cited by 638
Self-citationThe Role of Genes, Stress, and Dopamine in the Development of Schizophrenia
Howes, O. D., McCutcheon, R. A., Owen, M. J., & Murray, R. M. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.07.014 · Cited by 640
Kellendonk, C., Simpson, E. H., Polan, H. J., Malleret, G., Vronskaya, S., Winiger, V., Moore, H., & Kandel, E. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.023 · Cited by 520
Frank, M. J., & O'Reilly, R. C. (2006) · Behavioral Neuroscience · doi:10.1037/0735-7044.120.3.497 · Cited by 472
Metadata
- Authors
- Seeman, P., & Kapur, S.
- Affiliations
- University of Toronto (CA)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2000-07-05
- Volume
- 97
- Issue
- 14
- Pages
- 7673-7675
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC33999
- OpenAlex
- W2022725791
- Cited by
- 279
- References
- 22
- Citations by year
- 2026: 1 · 2025: 14 · 2024: 8 · 2023: 9 · 2022: 10 · 2021: 15 · 2020: 5 · 2019: 12 · 2018: 9 · 2017: 4 · 2016: 11 · 2015: 15 · 2014: 19 · 2013: 14 · 2012: 13
- FWCI
- 6.28
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- schizophrenia, dopamine hypothesis, dopamine D2 receptor, receptor occupancy, antipsychotic drugs, clozapine, quetiapine, receptor dissociation constant, schizophrenia pathophysiology
- MeSH terms
- Benzamides, Dopamine, Models, Biological, Psychotic Disorders, Pyrrolidines, Schizophrenia, Receptors, Dopamine D2, Dopamine Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
